← Leaderboards
Aarti Asnani
Beth Israel Deaconess Medical Center
$3,921,462
Attributed
$3,921,462
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $839.9K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,921,462 · 3
By mechanism
R01$2,606,962 · 1
K08$837,000 · 1
R21$477,500 · 1
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Ashok K Saluja$17,794,278
- Peter Goldman$805,098
- Barbara Wegiel$4,886,655
- Maria Serena Longhi$3,119,696
- Gordon F Sherman$139,625
Others in their field
Other Emerging Leaders on “Cardiomyopathies”
- Chanza Baytop · Westat, Inc.$271,217,917
- Federico Cividini · Cardiac Rsk3 Inhibitors, Llc$7,506,027
- Ryan L Boudreau · University Of Iowa$6,107,250
- Zhao Wang · Ut Southwestern Medical Center$5,743,143
- Yuichi Shimada · Columbia University Health Sciences$5,671,179
- Patricio Sepulveda · Amplo Biotechnology, Inc.$5,506,739
Research focus
CardiomyopathiesIsraelInvestigationPreventMetabolismMedical SchoolsPathway InteractionsMouse ModelToxic EffectDoxorubicinMalignant Breast NeoplasmCardiotoxicityMediatingMedical CenterHeart InjuriesCardioprotectionChemotherapyHeartCollaborationsGeneticMalignant NeoplasmsCancer TherapyAnthracyclineKnockout Mice
Grant awards (11)
Hemopexin as an Early Biomarker of Anthracycline Cardiac Toxicity$646,527
R01 · FY2025 · HL · contact PI
Hemopexin as an Early Biomarker of Anthracycline Cardiac Toxicity$633,596
R01 · FY2024 · HL · contact PI
Hemopexin as an Early Biomarker of Anthracycline Cardiac Toxicity$654,307
R01 · FY2023 · HL · contact PI
CYP1 Inhibition as a New Therapeutic Strategy for Doxorubicin Cardiomyopathy$167,400
K08 · FY2023 · HL · contact PI
Hemopexin as an Early Biomarker of Anthracycline Cardiac Toxicity$672,532
R01 · FY2022 · HL · contact PI
CYP1 Inhibition as a New Therapeutic Strategy for Doxorubicin Cardiomyopathy$167,400
K08 · FY2022 · HL · contact PI
CYP1 Inhibition as a New Therapeutic Strategy for Doxorubicin Cardiomyopathy$167,400
K08 · FY2021 · HL · contact PI
Sex-Specific Differences in the Development of Anthracycline Cardiotoxicity$218,750
R21 · FY2020 · HL · contact PI
CYP1 Inhibition as a New Therapeutic Strategy for Doxorubicin Cardiomyopathy$167,400
K08 · FY2020 · HL · contact PI
Sex-Specific Differences in the Development of Anthracycline Cardiotoxicity$258,750
R21 · FY2019 · HL · contact PI
CYP1 Inhibition as a New Therapeutic Strategy for Doxorubicin Cardiomyopathy$167,400
K08 · FY2019 · HL · contact PI